Although many see this policy shift as financially motivated, there is no doubt it will also help the cannabis industry normalize and destigmatize cannabis.
Political polarization could result in delaying the passage of new CBD legislation, which in turn would further hold up the implementation of a regulatory pathway for these products.
These letters continue to stress the need for Congress to enact legislation that will force the FDA to finally establish a regulatory pathway to govern CBD products intended for human and animal consumption.